These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 30499511)
1. [Structural changes in the ocular anterior segment against elevation of intraocular pressure after repeated intravitreal injections]. Budzinskaya MV; Bubnova IA; Kurguzova AG; Fettser EI Vestn Oftalmol; 2018; 134(5. Vyp. 2):156-161. PubMed ID: 30499511 [TBL] [Abstract][Full Text] [Related]
2. [Changes in intraocular pressure after intravitreal injections]. Bubnova IA; Kurguzova AG Vestn Oftalmol; 2018; 134(4):47-51. PubMed ID: 30166510 [TBL] [Abstract][Full Text] [Related]
3. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855 [TBL] [Abstract][Full Text] [Related]
4. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Frenkel MP; Haji SA; Frenkel RE Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773 [TBL] [Abstract][Full Text] [Related]
5. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness. Omay E; Elgin U; Sen E; Yilmazbas P Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098 [TBL] [Abstract][Full Text] [Related]
8. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613 [TBL] [Abstract][Full Text] [Related]
9. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure. Arslan GD; Guven D; Alkan AA; Kacar H; Demir M Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017 [No Abstract] [Full Text] [Related]
10. [Late and sustained intraocular pressure elevation related to intravitreal anti-VEGF injections: Cases requiring filtering surgery (French translation of the article)]. Leleu I; Penaud B; Blumen-Ohana E; Rodallec T; Adam R; Laplace O; Akesbi J; Nordmann JP J Fr Ophtalmol; 2018 Nov; 41(9):789-801. PubMed ID: 30348599 [TBL] [Abstract][Full Text] [Related]
11. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry. Fuest M; Kotliar K; Walter P; Plange N Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161 [TBL] [Abstract][Full Text] [Related]
12. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353 [TBL] [Abstract][Full Text] [Related]
13. [Changes in intraocular pressure and biometric parameters of the anterior segment of the eye after intravitreal injections]. Andreeva YS; Alkharki L; Budzinskaya MV Vestn Oftalmol; 2024; 140(2. Vyp. 2):7-15. PubMed ID: 38739125 [TBL] [Abstract][Full Text] [Related]
14. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465 [TBL] [Abstract][Full Text] [Related]
15. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499 [TBL] [Abstract][Full Text] [Related]
16. [Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs]. Andreeva YS; Alkharki L; Shelankova AV; Budzinskaya MV Vestn Oftalmol; 2024; 140(2. Vyp. 2):73-79. PubMed ID: 38739134 [TBL] [Abstract][Full Text] [Related]
17. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ichiyama Y; Sawada T; Kakinoki M; Sawada O; Nakashima T; Saishin Y; Kawamura H; Ohji M Ophthalmic Res; 2014; 52(4):234-8. PubMed ID: 25401265 [TBL] [Abstract][Full Text] [Related]
18. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400 [No Abstract] [Full Text] [Related]
19. [Evaluating the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration and concomitant glaucoma]. Erichev VP; Budzinskaya MV; Karpilova MA; Yulova AG; Smirnova TV; Andreeva IV; Shchegoleva IV; Plyukhova AA Vestn Oftalmol; 2015; 131(3):27-33. PubMed ID: 26310004 [TBL] [Abstract][Full Text] [Related]